Loading patent…
AssigneeCrystal Pharmaceutical (Suzhou) Co., Ltd.
InventorsMinhua CHEN, Yanfeng ZHANG, Po ZOU, Kai LIU, Xiaoyu ZHANG
Estimating the term…
The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.
A crystalline Form I of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 3.6°±0.2°, 12.7°±0.2° and 14.1°±0.2° using CuKα radiation.
A crystalline Form II of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 3.7°±0.2°, 4.5°±0.2° and 14.6°±0.2° using CuKα radiation.
A crystalline Form III of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 4.3°±0.2°, 14.6°±0.2° and 19.6°±0.2° using CuKα radiation.
A crystalline Form V of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 5.4°±0.2°, 9.9°±0.2° and 19.7°±0.2° using CuKα radiation.
A crystalline Form VI of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 4.8°±0.2°, 9.5°±0.2° and 14.5°±0.2° using CuKα radiation.
A crystalline Form VII of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 10.5°±0.2°, 13.8°±0.2° and 15.8°±0.2° using CuKα radiation.
A crystalline Form VIII of Sotagliflozin, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 6.2°±0.2°, 10.9°±0.2° and 17.7°±0.2° using CuKα radiation.
Dependencies are inferred from the claim text.